Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours Β· Estimated delivery Oct 17 - Oct 22
Many users report that the benefits continue to build over time with consistent use
Always review your plan with a clinician before starting
FOXO4-DRI acts as a competitive inhibitor of this interaction binding directly to the transactivation domain 2 (TAD2) of p53, displacing FOXO4, and allowing phosphorylated p53 to be exported from the nucleus and directed to mitochondria, where it activates BAX, triggers caspase-3 cleavage (via the p53/BCL-2/Caspase-3 signalling pathway), and drives cell-intrinsic apoptosis
Administering IGF-1 LR3 fasted or in a low-protein state wastes the growth factors anabolic potential because the cellular machinery is activated without the raw materials needed to execute protein synthesis
No formal drug interaction studies have been submitted to the FDA for this compound
US$ 23.88
US$ 24.35
US$ 24.59
US$ 25.13
US$ 28.57
